Sutro Biopharma (STRO) Accumulated Depreciation & Amortization (2017 - 2024)
Historic Accumulated Depreciation & Amortization for Sutro Biopharma (STRO) over the last 8 years, with Q4 2024 value amounting to $48.6 million.
- Sutro Biopharma's Accumulated Depreciation & Amortization rose 1533.81% to $48.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.6 million, marking a year-over-year increase of 1533.81%. This contributed to the annual value of $48.6 million for FY2024, which is 1533.81% up from last year.
- Sutro Biopharma's Accumulated Depreciation & Amortization amounted to $48.6 million in Q4 2024, which was up 1533.81% from $42.2 million recorded in Q4 2023.
- Over the past 5 years, Sutro Biopharma's Accumulated Depreciation & Amortization peaked at $48.6 million during Q4 2024, and registered a low of $33.4 million during Q4 2021.
- Its 5-year average for Accumulated Depreciation & Amortization is $39.8 million, with a median of $37.9 million in 2022.
- In the last 5 years, Sutro Biopharma's Accumulated Depreciation & Amortization crashed by 923.51% in 2021 and then surged by 1533.81% in 2024.
- Quarter analysis of 5 years shows Sutro Biopharma's Accumulated Depreciation & Amortization stood at $36.8 million in 2020, then dropped by 9.24% to $33.4 million in 2021, then grew by 13.4% to $37.9 million in 2022, then rose by 11.23% to $42.2 million in 2023, then increased by 15.34% to $48.6 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $48.6 million for Q4 2024, versus $42.2 million for Q4 2023 and $37.9 million for Q4 2022.